Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05939700 · ClinicalTrials.gov registry record
Mavacamten Pregnancy Surveillance Program
A clinical trial of Pregnancy Related and Breastfeeding, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05939700: Recruiting study of Pregnancy Related and Breastfeeding, sponsored by Bristol-Myers Squibb.
NCT05939700 is a study of Pregnancy Related and Breastfeeding that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants, below the 1,963-participant average among 99 other Pregnancy Related trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05939700, a study of Pregnancy Related and Breastfeeding, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
Primary Outcome
(1) Number of live births, full term or preterm births, stillbirths, spontaneous abortions, and elective abortions, (2) Number of participants with pregnancy complications
Conditions Studied
Interventions
- DRUG Mavacamten
Study Locations (1)
North Carolina
- The Mavacamten Pregnancy Surveillance Program, PPD Inc - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2027-04-30 |
What NCT05939700 shows while recruiting
NCT05939700 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,963-participant average among 99 other Pregnancy Related trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Pregnancy Related appearing as the primary indexed condition, and to 1 intervention - of which Mavacamten is the first listed.
NCT05939700 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05939700 about?
NCT05939700 is a clinical study titled "Mavacamten Pregnancy Surveillance Program". The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
What is the current status of trial NCT05939700?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-11-09. Estimated completion is 2027-04-30.
What conditions does trial NCT05939700 study?
This clinical trial studies the following conditions: Pregnancy Related, Breastfeeding, Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT05939700?
The interventions under investigation include: Mavacamten (DRUG).
Who is sponsoring clinical trial NCT05939700?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05939700 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05939700's enrollment target sits among peer trials
20 94th of 99 higher than 5 of 99 other Pregnancy Related trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy Related trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Antenatal Support for Iron Deficiency Anemia
RECRUITING · Phase 4
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
Mobile Application-based Exercise Intervention for Pregnant Women
RECRUITING · NA
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI